Royal Bank Of Canada Outlook Therapeutics, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $6,614 - $19,842	30,065 Added 135.29%	52,287 $20,000
Q3 2023 Nov 14, 2023	BUY	$0.2 - $1.78 $2,056 - $18,298	10,280 Added 86.08%	22,222 $4,000
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $2,035 - $3,772	1,996 Added 20.07%	11,942 $20,000
Q1 2023 May 15, 2023	SELL	$1.0 - $1.35 $7,978 - $10,770	-7,978 Reduced 44.51%	9,946 $10,000
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $14,337 - $21,918	16,480 Added 1141.27%	17,924 $19,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $788 - $973	773 Added 115.2%	1,444 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $5,758 - $12,719	-6,328 Reduced 90.41%	671 $1,000
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $16,516 - $27,482	-13,538 Reduced 65.92%	6,999 $12,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $12,341 - $21,671	9,718 Added 89.82%	20,537 $28,000
Q3 2021 Nov 15, 2021	SELL	$2.12 - $2.76 $77,428 - $100,803	-36,523 Reduced 77.15%	10,819 $23,000
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $84,268 - $130,663	47,342 New	47,342 $118,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.